Actinomycin-D
Information
- Drug Name
- Actinomycin-D
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Oncogenic BRAF causes chemoresistance by promoting... | BRAF | BRAF V600E | Resitance or Non-Reponse | true | MMMP | detail |
| The findings identify p38, TNFalpha and NFkB as ke... | TRAF2 | TRAF2 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT06020755 | Not yet recruiting | Phase 2 | Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 7 | September 2023 | August 2025 |
| NCT06028672 | Recruiting | N/A | Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6 | September 12, 2023 | August 2025 |
| NCT00491946 | Unknown status | Phase 4 | A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer | June 2004 |